Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified
Conditions
Interventions
Intervention1: Dalbavancin: Dalbavancin is a novel antibiotic.Each vial of Dalbavancin contains 500 mg powder, which is to be reconstituted and further diluted for IV infusion by using water for inje
Sponsors
Gufic Biosciences Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subjects must sign Informed Consent (ICF) prior to any evaluation and participation in the trial. 2. Male or female patients with age 18 - 65 years of age. 3. Patients who require hospitalization or already hospitalized patients with diagnosis of ABSSSIs. 4. Patients having an ABSSSIs confirmed to be caused by gram-positive bacteria defined for purposes of this study as an infection either involving deeper soft tissue or requiring significant surgical intervention. Patients with below mention condition will be included: a. Major cutaneous abscess characterized as a collection of pus within the dermis or deeper that is accompanied by erythema, edema and/or induration which: i. Requires surgical incision and drainage, and ii. Is associated with cellulitis such that the total affected area involves at least 75 cm2 of erythema, andiii. Alternatively, involves the central face and is associated with an area of erythema of at least 50 cm2. b. Surgical site or traumatic wound infection characterized by purulent drainage with surrounding erythema, edema and/or induration which occurred within 30 days after the trauma or surgery and is associated with cellulitis such that i. The total affected area involves at least 75 cm2 of erythema, and ii. Alternatively, involves the central face and is associated with an affected area of at least 50 cm2. c. Cellulitis, defined as a diffuse skin infection characterized by spreading areas of erythema, edema and/or induration and i. Is associated with erythema that involves at least 75 cm2 of surface area, or ii. Alternatively, cellulitis of the central face that is associated with an affected area of at least 50 cm2. (Note: Patients with Diabetes Mellitus having any of above-mentioned conditions OR patients with diabetic foot ulcer can also be included in the study). 5. Patients must be present with at least two local signs and symptoms of ABSSSIs in addition to erythema. a) Purulent drainage/discharge b) Fluctuance c) Heat/localized warmth d) Tenderness to palpation e) Swelling/induration 6. Patients must present with at least one of the following systemic signs of infection: i. An elevated body temperature = 38°C/100.4°F as measured by the patient/caregiver or investigator within 24 hours of baseline. ii. White blood cell count > 12,000 cells/mm3. 7. Requires a minimum of 3 days of IV therapy. 8. Patient willing and able to comply with study procedures.
Exclusion criteria
Exclusion criteria: 1. Infections caused exclusively by gram-negative bacteria or presence of gram-negative bacteria even in the presence of gram-positive bacteria and infections caused by fungi, whether alone or in combination with a bacterial pathogen. 2. Gram-negative bacteremia, even in the presence of gram-positive infection or gram-positive bacteremia. Note: If a gram-negative bacteremia develops during the study or is subsequently found to have been present at Baseline, the patient should be removed from study treatment and receive appropriate antibiotics to treat the gram-negative bacteremia. Such patients must have an EOT visit performed within 72 hours after discontinuing study medication but are required to have AEs reported through safety follow-up visit and a patient status at safety follow-up visit. 3. Subject with a contra-indication to dalbavancin, vancomycin, linezolid or any required study drug. 4. Patients with sustained shock, defined as systolic blood pressure 5. Participation in another study of an investigational drug or device within 30 days. 6. Patient with estimated creatinine clearance 7. Receipt of a systemically or topically administered antibiotic with a gram-positive spectrum that achieves therapeutic concentrations in the serum or at the site of the ABSSSIs within 14 days prior to randomization, except receipt of a single dose of a short-acting (half-life = 12 hours) antibacterial drug 3 or more days prior to randomization. 8. Patients with evidence of meningitis, necrotizing fasciitis, gas gangrene, gangrene, septic arthritis, osteomyelitis, endovascular infection, such as clinical and/or echocardiographic evidence of endocarditis or septic thrombophlebitis. 9. Venous catheter entry site infection. 10. Infections involving perirectal abscess or a decubitus ulcer. 11. Patient with an infected device, even if the device is removed. Examples include infection of: prosthetic cardiac valve, vascular graft, a pacemaker battery pack, joint prosthesis, hemodialysis catheter, implantable pacemaker or defibrillator, intra-aortic balloon pump, left ventricular assist device, a peritoneal dialysis catheter, or a neurosurgical device such as a ventricular peritoneal shunt, intra-cranial pressure monitor, or epidural catheter. 12. Patients whose ABSSSIs is the result of having sustained full or partial thickness burns. 13. Patients with an infection involving a limb with evidence of critical ischemia of an affected limb defined as any of the following criteria: absent or abnormal Doppler wave forms, toe blood pressure of 14. Patients with superficial/simple cellulitis/erysipelas, impetiginous lesion, furuncle, or simple abscess that only requires surgical drainage for cure. 15. Concomitant condition requiring any antibiotic therapy that would interfere with the assessment of study drug for the condition under study. 16. Anticipated need of antibiotic therapy for longer than 14 days. 17. Patients who are placed in a hyperbaric chamber as adjunctive therapy for ABSSSIs. 18. More than 2 surgical interventions for ABSSSIs anticipat
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To evaluate the early clinical efficacy of Dalbavancin (after 72 hours of therapy) in comparison with comparator regimen for the treatment of patients with a suspected or proven gram-positive ABSSSIs.Timepoint: 1. To evaluate the clinical efficacy of Dalbavancin at the end of treatment visit (EOT) compared to the comparator regimen. 2. To evaluate the clinical efficacy of dalbavancin at the follow up visits compared to the comparator regimen. 3. To evaluate the safety and tolerability of dalbavancin to that of comparator regimen. 4. To compare the per-patient microbiological efficacy of dalbavancin to the comparator regimen. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Clinical status at the EOT visit (study Day 14). 2) Clinical status at follow up visit.Timepoint: Clinical Status at 72 hours after the start of therapy and at the end of treatment i.e. Day 8 for IP group and day 14 for Comparator group. | — |
Countries
India
Contacts
Public ContactPranjal Ausekar
Gufic Biosciences Limited
Outcome results
None listed